2-YEAR OUTCOMES OF RISPERDAL(r) CONSTA(tm) - THE FIRST ATYPICAL LONG ACTING INJECTABLE ANTIPSYCHOTIC- RESULTS FROM THE CANADIAN NATIONAL OUTCOMES MEASUREMENT STUDY IN SCHIZOPHRENIA

Author(s)

Trakas K1, Talling D2, Balshaw R2, Love L2, Robinson K1, 1Janssen-Ortho Inc, Toronto, ON, Canada; 2Syreon Corporation, Vancouver, BC, Canada

Atypical antipsychotics (AAPs) are the cornerstone of therapy for schizophrenia based on their effective management of positive and negative symptoms. Clinical success is limited by partial compliance resulting in relapses. While conventional depot antipsychotics guarantee the delivery of medication the lack of a long-acting AAP has limited treatment options. OBJECTIVE: The purpose of this analysis was to examine outcomes for patients treated with the first long-acting AAP in Canada. METHODS: CNOMSS is an ongoing prospective, longitudinal, population-based epidemiological study involving 457 patients at 32 community and academic sites across Canada. Demographic and clinical data are collected for patients treated with antipsychotic medications under the conditions of routine clinical practice. This exploratory analysis included 21 patients treated with Risperdal Consta who completed at least 1 year of follow-up. RESULTS: While the majority (57.1%) of patients were considered "Mild" according to the Clinical Global Impression Rating Scale (CGI), significant improvement was seen over 2 years of observation (p = 0.033). Similarly, while most (47.6%) patients entered at baseline as "Much Improved" since their last visit prior to entry (CGI Improvement Rating Scale), they demonstrated improvement compared to baseline in both the first (p = 0.002) and second year (p = 0.007) of treatment. The Brief Psychiatric Rating Scale (BPRS) also demonstrated improvement over the first (p <0.001) and second (p = 0.056) years of observation. Discussion: While observational data is often exposed to selection bias, it is also a rich source of long-term outcomes for new therapies. Here we examine a small sample of patients treated with Risperdal Consta that demonstrate continued long-term improvement with this novel agent. CONCLUSION: The addition of a long-acting AAP to the psychiatrist's armamentarium has the potential to substantially improve outcomes in persons with schizophrenia in Canada.

Conference/Value in Health Info

2003-11, ISPOR Europe 2003, Barcelona, Spain

Value in Health, Vol. 6, No. 6 (November/December 2003)

Code

PMH4

Topic

Clinical Outcomes

Topic Subcategory

Comparative Effectiveness or Efficacy

Disease

Mental Health

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×